Good news: Corona vaccine will be available for only 225 rupees

There has been news in the country from Oxford's Serum Institute, which manufactures the vaccine. The Serum Institute of India has agreed with the Bill & Melinda Gates Foundation and Vaccine Alliance institution Gavi. Under this agreement, India and 92 low-income countries will be able to get the vaccine for just $ 3, or Rs 225. Please tell, Gavi is an institution of Gates Foundation. The purpose of which is to provide vaccine to the people of a low-income country. The vaccine is being distributed under the Kovacs scheme. The goal of the scheme is to deliver the vaccine of Kovid-19 to people around the world, including the World Health Organization. The agenda of the Kovacs Scheme is to provide vaccines to 200 crore people by 2021.

The Gates Foundation will provide funds to Gavi for the vaccine, which will be used to prepare and distribute the Serum Institute vaccine. The vaccine is likely to be available as soon as the human trials are completed. According to Serum Institute CEO Adar Poonawala, the vaccine may be available by the end of this year.

The vaccine will be launched under the name Covishield

Oxford University and the AstraZeneca company are developing the vaccine in collaboration with the Serum Institute of India. In India, this vaccine will be launched as Kovishield (AZD1222).

The trial will be done on a large scale

An agreement has been reached between the government and the Melinda Gates Foundation under the National Biopharma Mission and Grand Challenge India Program. Vaccine trials will be conducted on a large scale under this program only. Many institutes have been selected for this.

These include INCLEN of Palwal in Haryana, KEM Hospital in Pune, Society for Health Allied Research and Education in Hyderabad, National Institute of Epidemiology in Chennai, and Christian Medical College in Vellore.

Apart from this, AIIMS Delhi-Jodhpur, BJ Medical College, Pune, Rajendra Memorial Research Institute of Medical Sciences, Patna, JSS Academy, and Higher Education and Research in Mysore, Nehru Hospital in Gorakhpur, Andhra Medical College in Visakhapatnam and Post Graduate Institute of Chandigarh. Medical education and research are also included in this list.

Trials in Britain, Africa, and Brazil

Trial for this vaccine has started in Britain, South Africa, and Brazil. Its trial in India will begin in Mumbai and Pune in late August. In India, this vaccine will be launched as Kovishield. The company's CEO Adar Poonawala says that if the trial is successful, by the first quarter of 2021, 30-40 million doses will be ready. The vaccine may arrive by the end of this year.

The vaccine proved safe so far

According to a report published in the medical journal The Lancet, this vaccine is completely safe and effective. After this information, the vaccine front runner of Oxford has come forward in the list of vaccines. Oxford University has also said that applying this vaccine named AZD1222 has given a good immune response. The team involved in the vaccine trial and the Oxford Monitoring Group did not see any concerns about safety in this vaccine.